IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Microbiota And Autoimmune Diseases: Exploring Connections, Mechanisms, And Therapeutic Interventions

Vandana Jhalora[1], Renu Bist[1]

[1] Centre of Advanced Studies, Department of Zoology, University of Rajasthan, 302004

1. **Vandana Jhalora**
Research Scholar
Department of Zoology
Centre of Advanced Studies
University of Rajasthan
Jaipur-302004

2. **Corresponding Author**
Dr. Renu Bist
Associate Professor
Department of Zoology
Centre of Advanced Studies
University of Rajasthan
Jaipur-302004
Orcid ID: 0000-0003-2993-7983

ABSTRACT

Autoimmune diseases, characterized by the immune system attacking the body's own tissues, include conditions such as rheumatoid arthritis (RA), multiple sclerosis (MS), and systemic lupus erythematosus (SLE). Emerging evidence suggests that gut microbiota, the complex community of microorganisms residing in the gastrointestinal tract, plays a significant role in modulating immune responses and influencing autoimmune disease pathogenesis. This review explores the intricate relationship between gut microbiota and these autoimmune diseases, highlighting potential mechanisms and therapeutic interventions. Dysbiosis, or an imbalance in gut microbial composition, has been implicated in autoimmune disease development through several mechanisms, including increased intestinal permeability, molecular mimicry, and altered immune system regulation. In RA, dysbiosis can lead to systemic inflammation and contribute to joint damage. In MS, gut microbiota may influence central nervous system inflammation and blood-brain barrier integrity. In SLE, alterations in gut microbiota composition can affect autoantibody production and disease activity. Therapeutic interventions targeting gut microbiota, such as probiotics, prebiotics, faecal microbiota transplantation (FMT), and dietary modifications, offer promising approaches for managing autoimmune diseases. Probiotics and prebiotics can modulate gut microbiota composition and reduce inflammation, while FMT has potential for restoring a healthy microbiome. Dietary interventions, including anti-inflammatory diets, may also play a role in managing symptoms. Understanding the

connections between gut microbiota and autoimmune diseases could lead to novel strategies for prevention and treatment. Future research should focus on validating these therapeutic approaches and exploring personalized treatments based on individual microbiota profiles.

KEYWORDS- Autoimmune Diseases, Faecal Microbiota Transplantation, Multiple Sclerosis, Rheumatoid Arthritis, Systemic Lupus Erythematosus.

INTRODUCTION

Autoimmune diseases (ADs) occur when the immune system mistakenly targets and attacks the body's own tissues, resulting in chronic inflammation and organ damage. Common autoimmune diseases include rheumatoid arthritis (RA), multiple sclerosis (MS), and systemic lupus erythematosus (SLE) [1]. Traditional understanding of autoimmune disease pathogenesis involves genetic predisposition, environmental factors, and immune dysregulation. However, emerging evidence suggests that gut microbiota-a diverse community of microorganisms residing in the gastrointestinal tract-plays a crucial role in shaping immune responses and influencing autoimmune disease development [2,3].

The gut microbiota refers to the vast and diverse community of microorganisms, including bacteria, archaea, fungi, and viruses, residing in the gastrointestinal tract. These microbes play a crucial role in maintaining host health by modulating immune responses, maintaining intestinal barrier integrity, and influencing systemic inflammation. The gut microbiota communicates with the immune system through various mechanisms, including the production of microbial metabolites, modulation of immune cell function, and interaction with the gut-associated lymphoid tissue (GALT) [4].

A healthy gut microbiota is characterized by a balanced composition of microbial species, which supports immune tolerance and prevents excessive inflammation. Disruption of this balance, known as dysbiosis, can lead to alterations in immune system function and contribute to the development of autoimmune diseases [5]. Dysbiosis is often associated with increased intestinal permeability, allowing microbial antigens and inflammatory molecules to enter the bloodstream and trigger systemic inflammation.

Gut Microbiota and Autoimmune Diseases- The relationship between gut microbiota and autoimmune diseases is multifaceted and involves several potential mechanisms:

- Dysbiosis and Systemic Inflammation: In autoimmune diseases, changes in gut microbiota composition can lead to increased levels of pro-inflammatory bacteria and reduced levels of beneficial bacteria. This dysbiosis can promote systemic inflammation and contribute to disease pathogenesis. For example, in rheumatoid arthritis (RA), specific bacterial species have been associated with increased joint inflammation and damage such as *Porphyromonas gingivalis* [6], *Prevotella copri* [7], *Aggregatibacter actinomycetemcomitans* [8], and *Fusobacterium nucleatum* [9].
- Molecular Mimicry: Molecular mimicry occurs when microbial antigens share structural similarities with host tissues, leading to cross-reactivity and autoimmune responses [10]. Certain gut bacteria may possess antigens that mimic self-antigens, potentially triggering autoimmunity [11]. This mechanism has been implicated in diseases such as multiple sclerosis (MS), where microbial antigens may contribute to myelin sheath destruction.
- Immune System Modulation: Gut microbiota influences the development and function of immune cells, including T-helper cells, regulatory T cells, and B cells [12]. Dysbiosis can disrupt the balance of these immune cells, leading to an exaggerated autoimmune response. In SLE, alterations in gut microbiota have been associated with increased production of autoantibodies and disease flares [13].

1. RA: PATHOGENESIS AND MICROBIOTA INFLUENCE

RA is a chronic inflammatory joint disease characterized by synovial joint inflammation, cartilage destruction, and bone erosion. The exact cause of RA is unknown, but it is believed to involve a combination of genetic, environmental, and immune factors. Recent studies have identified alterations in gut microbiota composition in RA patients, with reduced diversity and abundance of certain beneficial bacteria.

The exact cause of RA remains unclear, but its development is thought to involve a combination of genetic, environmental, and immunological factors.

- **Genetic Factors:**

RA has a significant genetic component, with numerous susceptibility genes identified. The most well-known genetic risk factor is the presence of specific alleles of the human leukocyte antigen (HLA) gene, particularly HLA-DRB1 [14]. These alleles are associated with an increased risk of RA and are believed to influence how the immune system processes antigens.

- **Environmental Triggers:**

Environmental factors, such as smoking, infections, and exposure to certain pollutants, can trigger or exacerbate RA in genetically predisposed individuals. Smoking, in particular, is a well-established risk factor for RA and is thought to interact with genetic susceptibility to increase disease risk [15].

- **Immune Dysregulation:**

The pathogenesis of RA involves dysregulation of the immune system, leading to an inappropriate immune response against self-antigens. The immune system produces autoantibodies, such as rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPAs), which are often present in RA patients before the onset of clinical symptoms [16]. These autoantibodies contribute to the formation of immune complexes and subsequent inflammation in the joints.

- **Synovial Inflammation:**

In RA, the synovial membrane, which lines the joints, becomes inflamed (synovitis) (figure 1). This inflammation is driven by the infiltration of immune cells, such as T cells, B cells, and macrophages, into the synovial tissue. The inflammatory process leads to the production of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1), and interleukin-6 (IL-6), which perpetuate the inflammatory cycle and contribute to joint damage [17].

- **Joint Destruction:**

Chronic inflammation in RA results in the destruction of cartilage and bone. The inflammatory cells produce matrix metalloproteinases (MMPs) and other enzymes that degrade cartilage, leading to joint erosion and deformities [18].



Fig. 1 Illustration of the figure showing synovial inflammation

Influence of Gut Microbiota on RA

Emerging research suggests that gut microbiota-a diverse community of microorganisms residing in the gastrointestinal tract-plays a crucial role in modulating immune responses and influencing the development and progression of RA. The connection between gut microbiota and RA involves several potential mechanisms:

- **Dysbiosis and Systemic Inflammation:**

Dysbiosis, or an imbalance in gut microbiota composition, has been observed in RA patients. Studies have reported reduced diversity and altered composition of gut microbiota in individuals with RA compared to healthy controls. Specific bacterial taxa, such as *Prevotella* [7] and *Firmicutes* [19], have been found to be altered

in RA patients. Dysbiosis can lead to increased intestinal permeability, allowing microbial antigens and inflammatory molecules to enter the bloodstream and trigger systemic inflammation.

- **Molecular Mimicry:**

Molecular mimicry occurs when microbial antigens share structural similarities with host tissues, leading to cross-reactivity and autoimmune responses. Certain gut bacteria may possess antigens that mimic self-antigens, potentially triggering the immune system to attack joint tissues. For example, some studies suggest that microbial peptides may resemble citrullinated proteins, which are targeted by autoantibodies in RA.

- **Immune System Modulation:**

Gut microbiota influences the development and function of immune cells, including T-helper cells and regulatory T cells. Dysbiosis can disrupt the balance of these immune cells, leading to an exaggerated autoimmune response [20]. In RA, gut microbiota may impact the differentiation and activity of Th17 cells, which are involved in promoting inflammation and joint damage.

- **Microbial Metabolites:**

Gut bacteria produce metabolites that can influence immune function and inflammation. Short-chain fatty acids (SCFAs), such as butyrate, propionate, and acetate, are produced through the fermentation of dietary fibers by gut bacteria [21]. SCFAs have anti-inflammatory properties and can affect immune cell function. Dysbiosis can alter SCFA production, potentially contributing to increased inflammation and disease progression in RA.

- **Gut-Brain Axis and RA:**

The gut-brain axis refers to the bidirectional communication between the gut and the brain. Gut microbiota can influence brain function and stress responses, which in turn can affect immune system activity. Stress and changes in gut microbiota may contribute to the exacerbation of RA symptoms through increased systemic inflammation and altered immune responses [22].

2. MULTIPLE SCLEROSIS (MS)

MS is an autoimmune disease characterized by the destruction of myelin sheaths in the central nervous system (CNS), leading to neurological deficits and disability [23]. The pathogenesis of MS involves a combination of genetic susceptibility and environmental factors, including infections and gut microbiota.

Potential mechanisms linking gut microbiota to MS include:

- **Environmental Triggers:**

Environmental factors are believed to interact with genetic susceptibility to trigger MS. These factors include:

Infections: Viral infections, particularly Epstein-Barr virus (EBV), have been implicated in MS pathogenesis [24]. EBV infection can lead to the activation of autoreactive T cells and subsequent CNS inflammation.

Vitamin D Deficiency: Low levels of vitamin D have been associated with an increased risk of MS. Vitamin D is thought to influence immune function and may affect the development of MS [25].

Smoking: Smoking is a known risk factor for MS and may exacerbate disease progression by influencing immune responses and promoting inflammation [26].

- **Immune Dysregulation**:

The central pathological feature of MS is the immune-mediated destruction of myelin, the protective sheath surrounding nerve fibres. This process is characterized by:

Autoimmune Response: In MS, autoreactive T cells, particularly Th1 and Th17 cells, infiltrate the CNS and attack myelin, leading to demyelination and formation of plaques [27,28]. The activation of these T cells is facilitated by antigen-presenting cells (APCs), which present myelin antigens to T cells (figure 2).

Inflammatory Cascade: The infiltration of immune cells into the CNS triggers a cascade of inflammatory responses. Pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1), and interleukin-6 (IL-6), contribute to the inflammatory environment and damage to myelin [29,30].



Fig. 2 Pathogenesis of Multiple Sclerosis-The diagram illustrates the autoimmune attack on myelin sheaths by T cells and macrophages, leading to demyelination, axonal damage, and disrupted neural signaling in multiple sclerosis.

- **Axonal Damage**: Prolonged demyelination leads to axonal injury and neuronal loss. Axonal damage is a key factor in the progression of disability in MS [31].
- **Blood-Brain Barrier (BBB) Disruption**:
  BBB is a selective barrier that protects the CNS from harmful substances and immune cells. In MS, BBB disruption allows immune cells and inflammatory molecules to enter the CNS, contributing to disease progression [32]. The breakdown of the BBB is associated with increased disease activity and lesion formation.

Influence of Gut Microbiota on MS

Recent research has highlighted the significant role of gut microbiota in modulating immune responses and influencing the development and progression of MS. The gut microbiota, comprising a diverse community of microorganisms in the gastrointestinal tract, interacts with the immune system and affects systemic inflammation and CNS health.

- **Dysbiosis and Immune System Modulation**:
  Dysbiosis, or an imbalance in gut microbiota composition, has been observed in MS patients. Studies have reported altered gut microbiota profiles in individuals with MS compared to healthy controls. Specific bacterial taxa, such as *Firmicutes* and *Bacteroidetes*, may be affected in MS [33]. Dysbiosis can influence immune system function through several mechanisms:
  Immune Cell Differentiation: Gut microbiota plays a role in the differentiation and function of immune cells, including T-helper cells and regulatory T cells. Dysbiosis can disrupt the balance of these cells, leading to an exaggerated autoimmune response in MS. For example, altered microbiota may promote the differentiation of Th17 cells, which are involved in MS pathogenesis [34,35].
  Cytokine Production: Gut microbiota influences the production of cytokines, which are critical in regulating immune responses. Dysbiosis can lead to increased production of pro-inflammatory cytokines, contributing to systemic inflammation and CNS damage in MS [36,37].

- **Gut-Brain Axis and BBB Integrity**:
  The gut-brain axis refers to the bidirectional communication between the gut and the CNS. Gut microbiota can influence brain function and stress responses, which in turn can affect the BBB and disease activity in MS. Dysbiosis may affect BBB integrity through several mechanisms:

  Metabolite Production: Gut bacteria produce metabolites, such as short-chain fatty acids (SCFAs), that can impact BBB function. SCFAs, including butyrate, propionate, and acetate, have been shown to have anti-inflammatory effects and support BBB integrity [38]. Dysbiosis can alter SCFA production, potentially contributing to BBB disruption and increased disease activity in MS [39].

Immune System Communication: The gut microbiota interacts with the immune system and influences systemic inflammation. Dysbiosis can lead to increased inflammation and affect the permeability of the BBB, allowing immune cells and inflammatory molecules to enter the CNS [40,41].

3. SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

SLE is a chronic autoimmune disease characterized by the production of autoantibodies and multi-organ involvement. The pathogenesis of SLE involves genetic factors, hormonal influences, and environmental triggers, including gut microbiota [42]. The pathogenesis of SLE involves an interplay of genetic, environmental, and immunological factors.



Fig. 3 Figure showing the symptoms of Systemic Lupus Erythematosus

3.1 Genetic Factors:

Genetic predisposition is a significant contributor to SLE risk. Various genetic variants have been associated with an increased susceptibility to SLE, including:

HLA Genes: The human leukocyte antigen (HLA) gene complex, particularly the HLA-DR2 and HLA-DR3 alleles, is strongly associated with SLE [43]. These alleles influence antigen presentation and immune responses.
Non-HLA Genes: Other genetic loci, such as those related to the complement system (e.g., complement component 2 and 4) and interferon signaling (e.g., IRF5, STAT4), are also implicated in SLE [44–46]. These genes affect immune system regulation and inflammation.

3.2 Environmental Triggers:

Environmental factors interact with genetic susceptibility to trigger SLE. These include:

Infections: Viral infections, particularly with Epstein-Barr virus (EBV), have been linked to the onset and exacerbation of SLE [47]. EBV infection can induce the production of autoantibodies and activate autoreactive T cells [48] .
Sunlight Exposure: Ultraviolet (UV) light exposure can trigger skin lesions and exacerbate SLE symptoms [49]. UV light induces apoptosis in skin cells, leading to the release of nuclear antigens that can become targets of autoimmune responses [50].

3.3 Hormonal Factors:

Hormones, especially estrogen, are thought to play a role in SLE [51,52]. The higher prevalence of SLE in females and its association with hormonal changes suggest that estrogen may influence disease activity and progression [53].

3.4 Autoimmune Response:

SLE is characterized by a breakdown of self-tolerance and the development of autoreactive immune responses. Key features include:

Autoantibody Production: SLE patients produce a wide range of autoantibodies, including anti-nuclear antibodies (ANA), anti-double-stranded DNA (anti-dsDNA) antibodies, and anti-Smith (anti-Sm) antibodies [54]. These autoantibodies target various cellular components, including nuclear antigens.

Immune Complex Formation: Autoantibodies form immune complexes with their target antigens, which can deposit in tissues and organs, leading to inflammation and damage. Immune complexes contribute to the pathogenesis of SLE by triggering complement activation and inflammatory responses [55].

- **Cytokine Dysregulation:** Pro-inflammatory cytokines, such as interferon-alpha (IFN-alpha), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha), are elevated in SLE and contribute to disease activity [56]. These cytokines promote inflammation and influence immune cell function.

3.5 Organ Damage:

The inflammatory processes in SLE lead to damage in multiple organs, including:

Skin: SLE often presents with cutaneous manifestations, such as the characteristic butterfly-shaped rash on the face [57]. Photosensitivity and discoid lupus lesions are also common.

Kidneys: Lupus nephritis, an inflammation of the kidneys, is a severe complication of SLE [58]. It can lead to proteinuria, haematuria, and renal impairment.

Joints: Arthralgia and arthritis are frequent manifestations of SLE, contributing to joint pain and swelling [59].

Central Nervous System: Neuropsychiatric manifestations of SLE include cognitive dysfunction, seizures, and mood disorders [60].

Influence of Gut Microbiota on SLE

Recent research has elucidated the significant role of gut microbiota in influencing immune responses and contributing to the pathogenesis of SLE. The gut microbiota, a complex community of microorganisms residing in the gastrointestinal tract, interacts with the immune system and affects systemic inflammation and autoimmunity.

- **Immune System Modulation:**

Regulatory T Cells (Tregs): The presence of certain gut microbiota can promote the induction of Tregs, which are essential for maintaining immune tolerance. For instance, *Faecalibacterium prausnitzii* and *Akkermansia muciniphila* has been shown to have anti-inflammatory properties by inducing Tregs, which can help in reducing the autoimmune response in SLE [61].

Th17 Cells: Conversely, some gut bacteria can promote the differentiation of Th17 cells, which are implicated in the pathogenesis of autoimmune diseases including SLE. An imbalance favouring Th17 over Tregs can contribute to the progression of SLE [62].

- **Inflammatory Pathways:**

SCFAs: Gut microbiota produce SCFAs like butyrate, propionate, and acetate, which have anti-inflammatory effects. Butyrate, in particular, has been shown to suppress inflammatory responses and may have protective effects against SLE [63].

Lipopolysaccharides (LPS): Dysbiosis can lead to increased gut permeability and translocation of LPS into the bloodstream, which can trigger systemic inflammation and exacerbate SLE symptoms [64]

- **Microbial Dysbiosis in SLE Patients**:

Gut Microbiota Composition: Studies have shown that patients with SLE have distinct gut microbiota profiles compared to healthy individuals. For example, Hevia et al. (2014) reported a reduced abundance of *Lactobacillus* and *Bifidobacterium* species in SLE patients, which are known for their anti-inflammatory properties [65].

Pathobionts: Increased levels of pathobionts, such as *Enterococcus gallinarum*, have been found in SLE patients. These bacteria can translocate to other tissues and induce autoimmune responses [66,67].

- **Experimental Models:**

  Mouse Models: Germ-free mouse models have been used to demonstrate the influence of gut microbiota on SLE. For instance, transferring gut microbiota from SLE-prone mice to germ-free mice could induce lupus-like symptoms in the recipient mice [42,68].

THERAPEUTIC INTERVENTIONS

1. **Probiotics**: Probiotics are the live microorganisms that provide health benefits when consumed in adequate amounts, and are gaining attention for their potential in managing autoimmune diseases. They work primarily through several mechanisms such as restoring a healthy balance of gut microbiota, enhancing gut barrier function, modulating immune system activity, and producing beneficial compounds like short-chain fatty acids. By improving the balance of gut bacteria and reducing intestinal permeability, probiotics can help prevent the leakage of harmful substances into the bloodstream, which may trigger or exacerbate autoimmune responses. They also influence immune cells and inflammatory cytokines, potentially reducing inflammation and dampening excessive immune reactions.
   In autoimmune diseases such as RA, SLE, and MS, probiotics have shown promise. Clinical studies suggest that probiotics may help reduce disease activity, alleviate symptoms, and improve quality of life in RA patients. For SLE, probiotics may modulate immune responses and inflammation, although results are mixed and further research is needed. In MS, probiotics might influence immune activity and potentially reduce relapse rates, but more extensive studies are required to confirm their effectiveness. A randomized controlled trial by Vaghef-Mehrabany et al. (2014) investigated the effects of probiotic supplementation (*Lactobacillus casei*) in patients with RA. The study found significant improvements in disease activity score (DAS28), inflammatory markers (CRP and ESR), and a reduction in pro-inflammatory cytokines (IL-6 and TNF-α) in the probiotic group compared to the placebo group [69]. Mu et al. (2017) examined the impact of a probiotic (*Lactobacillus rhamnosus GG*) on gut microbiota composition and disease progression in an SLE mouse model. The results showed that probiotic treatment led to a significant reduction in anti-dsDNA antibodies, proteinuria, and renal histopathology scores, suggesting an amelioration of lupus symptoms [70].
   Despite the potential benefits, several challenges remain. The effects of probiotics are strain-specific, and determining the most effective strains and dosages for specific autoimmune diseases is essential. The safety and efficacy of probiotics should be carefully monitored, and quality control is crucial to ensure the potency and effectiveness of probiotic products. Overall, while probiotics offer a promising adjunctive treatment for autoimmune diseases, more research is needed to optimize their use and integrate them effectively into patient care.
2. **Prebiotics**: Prebiotics, non-digestible substances that promote the growth of beneficial gut bacteria, are increasingly recognized for their potential in managing autoimmune diseases. In autoimmune conditions like rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and multiple sclerosis (MS), prebiotics have shown potential benefits [71]. Studies suggest that prebiotics might help reduce systemic inflammation and modulate immune responses, contributing to improved disease management and symptom relief. A study explored the effects of inulin-type fructans (ITF) as a prebiotic in an animal model of RA. Mice treated with ITF showed a reduction in clinical arthritis scores, decreased inflammatory cytokines (IL-6, TNF-α), and altered gut microbiota composition with an increase in beneficial bacteria such as *Bifidobacterium* and *Lactobacillus* [72]. For instance, prebiotics could help lower levels of pro-inflammatory cytokines and support a balanced immune system, which may alleviate disease symptoms and reduce disease activity [73,74].
3. **Faecal Microbiota Transplantation (FMT)**: FMT, a procedure that involves transferring stool from a healthy donor to a patient, is emerging as a novel approach for managing autoimmune diseases [75]. The primary aim of FMT is to restore a balanced and diverse gut microbiota in patients who suffer from dysbiosis, an imbalance in gut bacteria often associated with autoimmune conditions. By reintroducing a healthy microbiota, FMT can help reestablish gut homeostasis, enhance gut barrier function, and reduce systemic inflammation. This restoration of microbial balance can potentially modulate immune responses and decrease the autoimmune activity that characterizes these diseases.
   In autoimmune disorders such as RA, SLE, and MS, FMT is being explored for its ability to improve clinical outcomes [76]. Early studies and clinical trials suggest that FMT may help reduce disease symptoms and improve disease management by correcting dysbiosis and influencing immune system function.
   Despite its potential, FMT remains experimental for most autoimmune diseases, with ongoing research needed to confirm its safety and efficacy [77]. Challenges include identifying the most effective donor stool preparations, optimizing administration routes, and understanding the long-term effects of FMT.

Personalized approaches, careful monitoring, and further studies are essential to fully harness the benefits of FMT in treating autoimmune diseases and integrating it into standard therapeutic practices.

CONCLUSION

The emerging evidence linking gut microbiota to autoimmune diseases such as RA, MS, and SLE highlights the complex interplay between the microbiome and immune system. Dysbiosis, immune modulation, and alterations in gut barrier function are key mechanisms by which gut microbiota may influence autoimmune disease development and progression. Therapeutic interventions targeting gut microbiota, including probiotics, prebiotics, faecal microbiota transplantation, and dietary modifications, hold promise for managing autoimmune diseases. Continued research is essential to elucidate the precise mechanisms by which gut microbiota contribute to autoimmune diseases and to develop effective microbiota-based therapies. Future studies should focus on large-scale clinical trials to confirm the efficacy of microbiota-targeted therapies and explore the potential for personalized interventions based on individual microbiota profiles. Advances in metagenomics and microbiome research will further enhance our understanding of the gut-brain-immune axis and its implications for autoimmune disease prevention and treatment.

REFERENCES

1. Frazzei, G., van Vollenhoven, R. F., de Jong, B. A., Siegelaar, S. E. & van Schaardenburg, D. Preclinical Autoimmune Disease: a Comparison of Rheumatoid Arthritis, Systemic Lupus Erythematosus, Multiple Sclerosis and Type 1 Diabetes. *Front Immunol* **13**, 899372 (2022).
2. Kinashi, Y. & Hase, K. Partners in Leaky Gut Syndrome: Intestinal Dysbiosis and Autoimmunity. *Front Immunol* **12**, 673708 (2021).
3. Wu, W.-J. H., Zegarra-Ruiz, D. F. & Diehl, G. E. Intestinal Microbes in Autoimmune and Inflammatory Disease. *Front Immunol* **11**, 597966 (2020).
4. Mörbe, U. M. *et al.* Human gut-associated lymphoid tissues (GALT); diversity, structure, and function. *Mucosal Immunol* **14**, 793–802 (2021).
5. Levy, M., Kolodziejczyk, A. A., Thaiss, C. A. & Elinav, E. Dysbiosis and the immune system. *Nat Rev Immunol* **17**, 219–232 (2017).
6. Perricone, C. *et al.* Porphyromonas gingivalis and rheumatoid arthritis. *Curr Opin Rheumatol* **31**, 517–524 (2019).
7. Alpizar-Rodriguez, D. *et al.* Prevotella copri in individuals at risk for rheumatoid arthritis. *Ann Rheum Dis* **78**, 590–593 (2019).
8. Svärd, A. *et al.* Presence and Immunoreactivity of Aggregatibacter actinomycetemcomitans in Rheumatoid Arthritis. *Pathogens* **13**, 368 (2024).
9. Tang, W., Liu, Z. Y. & Abreu, C. Fusobacterium nucleatum Pleural Empyema in a Patient with Progressive Rheumatoid Arthritis and Immunosuppression. *Case Rep Infect Dis* **2021**, 5212401 (2021).
10. Rojas, M. *et al.* Molecular mimicry and autoimmunity in the time of COVID-19. *J Autoimmun* **139**, 103070 (2023).
11. Hall, R. Molecular mimicry. *Adv Parasitol* **34**, 81–132 (1994).
12. D'Amelio, P. & Sassi, F. Gut Microbiota, Immune System, and Bone. *Calcif Tissue Int* **102**, 415–425 (2018).
13. Pan, Q. *et al.* Gut Microbiota Dysbiosis in Systemic Lupus Erythematosus: Novel Insights into Mechanisms and Promising Therapeutic Strategies. *Front Immunol* **12**, 799788 (2021).
14. van Drongelen, V. & Holoshitz, J. HLA-Disease Associations in Rheumatoid Arthritis. *Rheum Dis Clin North Am* **43**, 363–376 (2017).
15. Chang, K. *et al.* Smoking and Rheumatoid Arthritis. *Int J Mol Sci* **15**, 22279–22295 (2014).
16. de Brito Rocha, S., Baldo, D. C. & Andrade, L. E. C. Clinical and pathophysiologic relevance of autoantibodies in rheumatoid arthritis. *Adv Rheumatol* **59**, 1–13 (2019).
17. Zhang, J.-M. & An, J. Cytokines, Inflammation and Pain. *Int Anesthesiol Clin* **45**, 27–37 (2007).
18. Rose, B. J. & Kooyman, D. L. A Tale of Two Joints: The Role of Matrix Metalloproteases in Cartilage Biology. *Dis Markers* **2016**, 4895050 (2016).
19. Wang, Q. *et al.* Characteristics of the Gut Microbiome and Its Relationship With Peripheral CD4+ T Cell Subpopulations and Cytokines in Rheumatoid Arthritis. *Front. Microbiol.* **13**, (2022).
20. Carding, S., Verbeke, K., Vipond, D. T., Corfe, B. M. & Owen, L. J. Dysbiosis of the gut microbiota in disease. *Microb Ecol Health Dis* **26**, 10.3402/mehd.v26.26191 (2015).

21. den Besten, G. *et al.* The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. *J Lipid Res* **54**, 2325–2340 (2013).
22. Horta-Baas, G. *et al.* Intestinal Dysbiosis and Rheumatoid Arthritis: A Link between Gut Microbiota and the Pathogenesis of Rheumatoid Arthritis. *J Immunol Res* **2017**, 4835189 (2017).
23. Dobson, R. & Giovannoni, G. Multiple sclerosis - a review. *Eur J Neurol* **26**, 27–40 (2019).
24. Fyfe, I. T cells implicate Epstein–Barr virus in multiple sclerosis pathogenesis. *Nat Rev Neurol* **20**, 133–133 (2024).
25. Gombash, S. E., Lee, P. W., Sawdai, E. & Lovett-Racke, A. E. Vitamin D as a Risk Factor for Multiple Sclerosis: Immunoregulatory or Neuroprotective? *Front. Neurol.* **13**, (2022).
26. Wingerchuk, D. M. Smoking: effects on multiple sclerosis susceptibility and disease progression. *Ther Adv Neurol Disord* **5**, 13–22 (2012).
27. Fletcher, J. M., Lalor, S. J., Sweeney, C. M., Tubridy, N. & Mills, K. H. G. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. *Clin Exp Immunol* **162**, 1–11 (2010).
28. Rostami, A. & Ciric, B. Role of Th17 cells in the pathogenesis of CNS inflammatory demyelination. *J Neurol Sci* **333**, 76–87 (2013).
29. Kany, S., Vollrath, J. T. & Relja, B. Cytokines in Inflammatory Disease. *International Journal of Molecular Sciences* **20**, 6008 (2019).
30. Leal, M. C., Casabona, J. C., Puntel, M. & Pitossi, F. Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson's Disease? *Front. Cell. Neurosci.* **7**, (2013).
31. Haines, J. D., Inglese, M. & Casaccia, P. Axonal Damage in Multiple Sclerosis. *Mt Sinai J Med* **78**, 231–243 (2011).
32. Zierfuss, B., Larochelle, C. & Prat, A. Blood–brain barrier dysfunction in multiple sclerosis: causes, consequences, and potential effects of therapies. *The Lancet Neurology* **23**, 95–109 (2024).
33. Kirby, T. O. & Ochoa-Repáraz, J. The Gut Microbiome in Multiple Sclerosis: A Potential Therapeutic Avenue. *Medical Sciences* **6**, 69 (2018).
34. Sun, C.-Y., Yang, N., Zheng, Z.-L., Liu, D. & Xu, Q.-L. T helper 17 (Th17) cell responses to the gut microbiota in human diseases. *Biomedicine & Pharmacotherapy* **161**, 114483 (2023).
35. Yadav, S. K., Ito, K. & Dhib-Jalbut, S. Interaction of the Gut Microbiome and Immunity in Multiple Sclerosis: Impact of Diet and Immune Therapy. *Int J Mol Sci* **24**, 14756 (2023).
36. Garvey, M. The Association between Dysbiosis and Neurological Conditions Often Manifesting with Chronic Pain. *Biomedicines* **11**, 748 (2023).
37. Sadeghpour Heravi, F. Gut Microbiota and Autoimmune Diseases: Mechanisms, Treatment, Challenges, and Future Recommendations. *Curr Clin Micro Rpt* **11**, 18–33 (2024).
38. Silva, Y. P., Bernardi, A. & Frozza, R. L. The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication. *Front Endocrinol (Lausanne)* **11**, 25 (2020).
39. Ordoñez-Rodriguez, A., Roman, P., Rueda-Ruzafa, L., Campos-Rios, A. & Cardona, D. Changes in Gut Microbiota and Multiple Sclerosis: A Systematic Review. *Int J Environ Res Public Health* **20**, 4624 (2023).
40. Solanki, R., Karande, A. & Ranganathan, P. Emerging role of gut microbiota dysbiosis in neuroinflammation and neurodegeneration. *Front Neurol* **14**, 1149618 (2023).
41. Tang, W., Zhu, H., Feng, Y., Guo, R. & Wan, D. The Impact of Gut Microbiota Disorders on the Blood–Brain Barrier. *Infect Drug Resist* **13**, 3351–3363 (2020).
42. Toumi, E. *et al.* Gut microbiota in SLE: from animal models to clinical evidence and pharmacological perspectives. *Lupus Sci Med* **10**, e000776 (2023).
43. Cruz-Tapias, P., Castiblanco, J. & Anaya, J.-M. HLA Association with Autoimmune Diseases. in *Autoimmunity: From Bench to Bedside [Internet]* (El Rosario University Press, 2013).
44. Londe, A. C., Fernandez-Ruiz, R., Julio, P. R., Appenzeller, S. & Niewold, T. B. Type I Interferons in Autoimmunity: Implications in Clinical Phenotypes and Treatment Response. *The Journal of Rheumatology* **50**, 1103–1113 (2023).
45. Postal, M. *et al.* Type I interferon in the pathogenesis of systemic lupus erythematosus. *Curr Opin Immunol* **67**, 87–94 (2020).
46. Sigurdsson, S. *et al.* A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5. *Human Molecular Genetics* **17**, 2868–2876 (2008).
47. Banko, A. *et al.* Epstein-Barr virus infection as potential indicator of the occurrence and clinical presentation of systemic lupus erythematosus. *Front. Immunol.* **14**, (2023).

48. Nagata, K. & Hayashi, K. Epstein–Barr Virus Reactivation-Induced Immunoglobulin Production: Significance on Autoimmunity. *Microorganisms* **8**, 1875 (2020).
49. Kim, A. & Chong, B. F. Photosensitivity in Cutaneous Lupus Erythematosus. *Photodermatol Photoimmunol Photomed* **29**, 4–11 (2013).
50. Lee, C.-H., Wu, S.-B., Hong, C.-H., Yu, H.-S. & Wei, Y.-H. Molecular Mechanisms of UV-Induced Apoptosis and Its Effects on Skin Residential Cells: The Implication in UV-Based Phototherapy. *Int J Mol Sci* **14**, 6414–6435 (2013).
51. Kim, J.-W., Kim, H.-A., Suh, C.-H. & Jung, J.-Y. Sex hormones affect the pathogenesis and clinical characteristics of systemic lupus erythematosus. *Front Med (Lausanne)* **9**, 906475 (2022).
52. Wu, D. *et al.* Characteristics of steroid hormones in systemic lupus erythematosus revealed by GC/MS-based metabolic profiling. *Front. Endocrinol.* **14**, (2023).
53. Sachdeva, R. & Pal, R. The influence of reproductive hormones on systemic lupus erythematosus. *Explor Immunol.* **2**, 351–362 (2022).
54. Dema, B. & Charles, N. Autoantibodies in SLE: Specificities, Isotypes and Receptors. *Antibodies (Basel)* **5**, 2 (2016).
55. Macedo, A. C. L. & Isaac, L. Systemic Lupus Erythematosus and Deficiencies of Early Components of the Complement Classical Pathway. *Front. Immunol.* **7**, (2016).
56. Richter, P. *et al.* Cytokines in Systemic Lupus Erythematosus—Focus on TNF-α and IL-17. *Int J Mol Sci* **24**, 14413 (2023).
57. COJOCARU, M., COJOCARU, I. M., SILOSI, I. & VRABIE, C. D. Manifestations of Systemic Lupus Erythematosus. *Maedica (Bucur)* **6**, 330–336 (2011).
58. de Zubiria Salgado, A. & Herrera-Diaz, C. Lupus Nephritis: An Overview of Recent Findings. *Autoimmune Dis* **2012**, 849684 (2012).
59. Ceccarelli, F. *et al.* Arthritis in Systemic Lupus Erythematosus: From 2022 International GISEA/OEG Symposium. *Journal of Clinical Medicine* **11**, 6016 (2022).
60. Gulinello, M., Wen, J. & Putterman, C. Neuropsychiatric Symptoms in Lupus. *Psychiatr Ann* **42**, 322–328 (2012).
61. Effendi, R. M. R. A. *et al.* Akkermansia muciniphila and Faecalibacterium prausnitzii in Immune-Related Diseases. *Microorganisms* **10**, 2382 (2022).
62. Kamada, N., Seo, S.-U., Chen, G. Y. & Núñez, G. Role of the gut microbiota in immunity and inflammatory disease. *Nat Rev Immunol* **13**, 321–335 (2013).
63. Anshory, M. *et al.* Butyrate Properties in Immune-Related Diseases: Friend or Foe? *Fermentation* **9**, 205 (2023).
64. Charoensappakit, A., Sae-khow, K. & Leelahavanichkul, A. Gut Barrier Damage and Gut Translocation of Pathogen Molecules in Lupus, an Impact of Innate Immunity (Macrophages and Neutrophils) in Autoimmune Disease. *Int J Mol Sci* **23**, 8223 (2022).
65. Hevia, A. *et al.* Intestinal dysbiosis associated with systemic lupus erythematosus. *mBio* **5**, e01548-01514 (2014).
66. Bagavant, H. *et al.* Immune Response to Enterococcus gallinarum in Lupus Patients Is Associated With a Subset of Lupus-Associated Autoantibodies. *Front Immunol* **12**, 635072 (2021).
67. Bogdanos, D. P. & Sakkas, L. I. Enterococcus gallinarum as a component of the Autoinfectome: the gut-liver-autoimmune rheumatic disease axis is alive and kicking. *Mediterranean Journal of Rheumatology* **29**, 187 (2018).
68. Lu, R. & Luo, X. M. The role of gut microbiota in different murine models of systemic lupus erythematosus. *Autoimmunity* **57**, 2378876 (2024).
69. Vaghef-Mehrabany, E. *et al.* Probiotic supplementation improves inflammatory status in patients with rheumatoid arthritis. *Nutrition* **30**, 430–435 (2014).
70. Mu, Q. *et al.* Control of lupus nephritis by changes of gut microbiota. *Microbiome* **5**, 73 (2017).
71. Giri, P. S., Shah, F. & Dwivedi, M. K. Chapter 12 - Probiotics and prebiotics in the suppression of autoimmune diseases. in *Probiotics in the Prevention and Management of Human Diseases* (eds. Dwivedi, M. K., Amaresan, N., Sankaranarayanan, A. & Kemp, E. H.) 161–186 (Academic Press, 2022). doi:10.1016/B978-0-12-823733-5.00019-2.
72. Hussain, M. A., Haseeb, M. T., Muhammad, G. & Tahir, M. N. Inulin Type Fructan: A Versatile Functional Material for Food and Healthcare. in *Functional Biopolymers* (eds. Jafar Mazumder, M. A., Sheardown, H. & Al-Ahmed, A.) 1–22 (Springer International Publishing, Cham, 2019). doi:10.1007/978-3-319-92066-5_20-1.

73. Pujari, R. & Banerjee, G. Impact of prebiotics on immune response: from the bench to the clinic. *Immunology & Cell Biology* **99**, 255–273 (2021).
74. Zhou, P., Chen, C., Patil, S. & Dong, S. Unveiling the therapeutic symphony of probiotics, prebiotics, and postbiotics in gut-immune harmony. *Front. Nutr.* **11**, (2024).
75. Seida, I., Al Shawaf, M. & Mahroum, N. Fecal microbiota transplantation in autoimmune diseases – An extensive paper on a pathogenetic therapy. *Autoimmunity Reviews* 103541 (2024) doi:10.1016/j.autrev.2024.103541.
76. Yang, R., Chen, Z. & Cai, J. Fecal microbiota transplantation: Emerging applications in autoimmune diseases. *Journal of Autoimmunity* **141**, 103038 (2023).
77. Zeng, L. *et al.* Safety and efficacy of fecal microbiota transplantation for autoimmune diseases and autoinflammatory diseases: A systematic review and meta-analysis. *Front Immunol* **13**, 944387 (2022).